Study Suggests Different Approach After Progression In NSCLC Patients

Source : International Association for the Study of Lung Cancer

While more research needed, chemotherapy might not be best treatment

DENVER – Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib or EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, respectively. However, progression inevitably occurs. When it does, having no clear guidelines and/or indications, most patients are treated with chemotherapy. A new study published in the December 2012 issue of the International Association for the Study of Lung Cancer’s (IASLC) Journal of Thoracic Oncology, shows that other approaches to overcome acquired resistance should be considered.

Researchers looked at NSCLC patients with histologically confirmed ALK rearrangements or EGFR mutations who were treated with crizotinib or erlotinib at the University of Colorado Cancer Center between May 2005 and December 2011.

Of the 51 patients whose cancer grew eventually on the targeted drugs, 25 were deemed suitable for local ablative therapy radiotherapy or surgery) to the site of progression, and then continued on the same drug. The use of this strategy prolonged the duration of disease control by the drug by 6.2 months, on top of the median of 9.8 months initial disease control. The benefit was most marked in patients who only experienced isolated growth in the brain – this group had another median 7.1 months of disease control before further growth either in the body and brain.

While the authors point out study limitations and the need for further research, they say their experience suggests that when NSCLC patients with EGFR mutations or ALK rearrangements “progress on erlotinib or crizotinib, respectively, and the progression occurs in only a limited number of sites (oligoprogressive disease) it may be reasonable to consider LAT to the sites of progression and continuation of the TKI.”

The lead author of this work is IASLC member Dr. Andrew Weickhardt. Co-authors include IASLC members Dr. Paul Bunn, Dr. Dara Aisner, Dr. Laurie Gaspar, Dr. Robert Doebele and Dr. Ross Camidge.

About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 3,500 lung cancer specialists in 80 countries. To learn more about IASLC please visit www.iaslc.org.

  • <<
  • >>

Articles List

  • Analyze Your Sequence Data with Bioconductor

    Analyze Your Sequence Data with Bioconductor

    Bioconductor has become a leading option for researchers to effectively progress through the wealth of NGS and other types of experimental data collected. Here's what you need to know.
  • Characterizing the Microbiome

    Characterizing the Microbiome

    The microbiome is the community of all the microorganisms in a location. Microbiomics, in turn, is the study of that community and its ecosystem. Microbiomists use high-throughput sequencing, mass spectrometry, biochemical analysis and other tools to figure out which organisms are present, how many of each there are, what genes they carry, what RNAs they express, what proteins they make and what metabolites they generate. Often, the goal is to gain a better understanding of the relationships among community members so as ultimately to be able to manipulate them.

Disqus Comments